An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aurinia Pharmaceuticals Inc. (AUPH) is set to release its 2023 fourth quarter and full year financial and operational results on February 15, 2024. The management team will host a conference call/webcast to review the results and provide a general business update. Interested participants can access the webcast through the company's corporate website.
Positive
None.
Negative
None.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney, and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
When will Aurinia Pharmaceuticals release its 2023 fourth quarter and full year financial and operational results?
Aurinia Pharmaceuticals will release its 2023 fourth quarter and full year financial and operational results on February 15, 2024.
How can interested participants access the conference call/webcast?
Interested participants can access the conference call/webcast through the 'News/Events' section of the Aurinia corporate website at www.auriniapharma.com.
What are the dial-in details for the conference call?
Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) to join the conference call.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available on Aurinia’s website.
